Title |
Bevacizumab in the Treatment of Ovarian Cancer
|
---|---|
Published in |
Advances in Therapy, August 2012
|
DOI | 10.1007/s12325-012-0041-9 |
Pubmed ID | |
Authors |
Florian Heitz, Philipp Harter, Jana Barinoff, Bianca Beutel, Paevi Kannisto, Jacek P. Grabowski, Julia Heitz, Christian Kurzeder, Andreas du Bois |
Abstract |
In the past decade there have been many attempts to improve systemic treatment and thus the outcome of patients with ovarian cancer. However, neither the sequential addition of non cross-resistant drugs to standard chemotherapy comprising carboplatin and paclitaxel, nor triplet combination therapies with conventional chemotherapeutic drugs have improved outcomes. Instead, such approaches have led to an increase in the incidence of side effects. We are currently experiencing a shift toward the addition of molecularly targeted and biological anticancer therapies to standard treatment. Vascular endothelial growth factor (VEGF), which improves vitally important tumor vasculature, is secreted by a range of tumors, and a high level of VEGF is known to be an independent risk factor for aggressive disease in ovarian cancer. This finding led to the development in the 1990s of bevacizumab, a humanized monoclonal antibody against VEGF. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
South Africa | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
India | 1 | 1% |
Portugal | 1 | 1% |
Unknown | 67 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 20% |
Student > Master | 10 | 14% |
Student > Bachelor | 8 | 11% |
Student > Ph. D. Student | 7 | 10% |
Professor | 6 | 8% |
Other | 14 | 20% |
Unknown | 12 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 37% |
Biochemistry, Genetics and Molecular Biology | 9 | 13% |
Agricultural and Biological Sciences | 9 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
Computer Science | 2 | 3% |
Other | 8 | 11% |
Unknown | 12 | 17% |